Logo
x

Search

Subscribe Now

All Posts by Date

PharmaShots Interview: Novartis’ Todd Fox Shares Insight on the US FDA's Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis

PharmaShots Interview: Novartis’ Todd Fox Shares Insight on the US FDA's Approval of Cosentyx for Enthesitis-Related Arthritis and...

  • February 22, 2022
OBI Entered into an Exclusive License Agreement with Odeon for OBI-999 and OBI-833 to Treat Cancer in China, Hong Kong and Macau

OBI Entered into an Exclusive License Agreement with Odeon for OBI-999 and OBI-833 to Treat Cancer in China, Hong Kong and Macau

  • February 22, 2022
InnoCare Reports First Patient Dosing of Orelabrutinib in P-II Clinical Trial for the Treatment of ITP

InnoCare Reports First Patient Dosing of Orelabrutinib in P-II Clinical Trial for the Treatment of ITP

  • February 22, 2022
Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Clinical Trial for the Treatment of Active Crohn's Disease at ECCO 2022

Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Clinical Trial for the Treatment of Active Crohn's Disease at...

  • February 22, 2022
Abbott's CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure

Abbott's CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure

  • February 22, 2022
Ono’s Velexbru Receives the TFDA’s Approval for the Treatment of B-cell Primary Central Nervous System Lymphoma in Taiwan

Ono’s Velexbru Receives the TFDA’s Approval for the Treatment of B-cell Primary Central Nervous System Lymphoma in Taiwan

  • February 22, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.